Oregon Mesothelioma Doctors, Cancer Centers and Treatment

People diagnosed with mesothelioma who live in Oregon have access to a number of quality health care options. Conventional mesothelioma treatments available in Oregon include surgery, chemotherapy and radiation. Beyond these conventional treatments, clinical trials may currently be recruiting pleural and peritoneal mesothelioma patients in Oregon.

Quickly diagnosing, staging and beginning a solid treatment plan gives one the best chance for improving life expectancy. We have listed top mesothelioma doctors that practice in Oregon as well as the top cancer care centers in the state. A number of local cancer support services has been included as well for your convenience.

Mesothelioma Cancer Centers in Oregon

Quality cancer treament services are available at the following mesothelioma cancer centers in Oregon. More detailed information about each cancer center is available by clicking on the appropriate a cancer center detail link.

Top Oregon Mesothelioma Doctors

We have compiled a list of mesothelioma doctors that practice in the state of Oregon. Please click on a doctor link to obtain more information about his/her background, areas of expertise, professional affiliations, and office locations.

It is not uncommon for patients to travel outside of their current states to meet with top oncologists and thoracic surgeons across the country. These mesothelioma experts usually have a particular focus within their practice.

Mesothelioma Clinical Trials in Oregon

The following clinical trials are in progress or actively recruiting participants in the state of Oregon:

• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  Conditions:	Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
  Last Updated:	July 8, 2019
  Status:	Recruiting
  Locations:	Baker City, OR. Bend, OR. Clackamas, OR. Coos Bay, OR. Gresham, OR. Newberg, OR. Ontario, OR. Oregon City, OR. Portland, OR. Redmond, OR.

• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

  Conditions:	Advanced Malignancies; Metastatic Cancer
  Last Updated:	June 19, 2019
  Status:	Recruiting
  Locations:	Portland, OR. Los Angeles, CA. Gainesville, FL. Detroit, MI. Saint Louis, MO. Hackensack, NJ. New York, NY. Chapel Hill, NC. Oklahoma City, OK. Philadelphia, PA.

• A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

  Conditions:	Melanoma; Breast Carcinoma; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Colorectal Carcinoma; Non-small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma; Mesothelioma; Neuroendocrine Carcinoma; Cervical Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of the Anus
  Last Updated:	April 29, 2019
  Status:	Recruiting
  Locations:	Portland, OR. Los Angeles, CA. San Diego, CA. San Francisco, CA. Atlanta, GA. Chicago, IL. Fairway, KS. Detroit, MI. New York, NY. Philadelphia, PA.

• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

  Conditions:	Advanced Malignancies
  Last Updated:	April 26, 2019
  Status:	Active, not recruiting
  Locations:	Portland, OR. Birmingham, AL. Scottsdale, AZ. Los Angeles, CA. Miami, FL. Ann Arbor, MI. Detroit, MI. Hackensack, NJ. New Brunswick, NJ. New York, NY.

• Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

  Conditions:	Malignant Mesothelioma
  Last Updated:	March 4, 2019
  Status:	Active, not recruiting
  Locations:	Clackamas, OR. Milwaukie, OR. Newberg, OR. Oregon City, OR. Portland, OR. Scottsdale, AZ. San Francisco, CA. Hartford, CT. New Britain, CT. Lewes, DE.

Cancer Support Services in Oregon

Cancer support services for mesothelioma patients include patient transport, temporary housing, physical therapy and counseling. The following local services may be of help to you while you are receiving treatment for mesothelioma in Oregon.

Free 2019 Mesothelioma Treatment Guide & Books

Delivered to you within 24 hours